

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 November 2019 (21.11.2019)



(10) International Publication Number
WO 2019/222529 A1

(51) International Patent Classification:

A61K 47/64 (2017.01) C12N 9/64 (2006.01)

(21) International Application Number:

PCT/US2019/032710

(22) International Filing Date:

16 May 2019 (16.05.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/672,187 16 May 2018 (16.05.2018) US

(71) Applicant: **LIB THERAPEUTICS, LLC** [US/US]; 5375 Medpace Way, Cincinnati, OH 45227 (US).

(72) Inventor: **MITCHELL, Tracy, S.**; c/o Lib Therapeutics, LLC, 5375 Medpace Way, Cincinnati, OH 45227 (US).

(72) Inventor: **MEALEY, Richard** (deceased).

(74) Agent: **HAYMAN, Mark, L.** et al.; Morgan, Lewis & Bockius LLP, 1111 Pennsylvania Avenue, NW, Washington, DC 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,


CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: COMPOSITIONS COMPRISING PCSK9-BINDING MOLECULES AND METHODS OF USE



HSA = human serum albumin; PCSK9 = proprotein convertase subtilisin/kexin type 9.

Figure 1

(57) Abstract: The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).



WO 2019/222529 A1